← Human Trials & Peer-Reviewed Studies
Sequential Therapy With Recombinant Human IGF-1 Followed by Risedronate Increases Spine Bone Mineral Density in Women With Anorexia Nervosa: A Randomized, Placebo-Controlled Trial
Plain-language guide to PMID 34355814 (2021): placebo-controlled randomized controlled trial study of IGF-1 LR3 and Mecasermin (rhIGF-1) in 90 women.
Key Facts
- PMID
- 34355814
- Journal
- Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
- Year
- 2021
- Study type
- Randomized Controlled Trial
- Authors
- Haines MS et al. (21 authors)
- DOI
- 10.1002/jbmr.4420
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of IGF-1 LR3 and Mecasermin (rhIGF-1), published as a randomized controlled trial.
The lumbar spine is most severely affected.
The researchers conducted a 12-month, randomized, placebo-controlled study of 90 ambulatory women with anorexia nervosa and low areal BMD (aBMD).
Who Took Part
The study group was 90 women.
PubMed tags the participants as women only.
Participants were randomized to three groups: 6 months of rhIGF-1 followed by 6 months of risedronate ("rhIGF-1/Risedronate") (n = 33), 12 months of risedronate ("Risedronate") (n = 33), or double placebo ("Placebo") (n = 16).
How the Study Was Run
The design is described as randomized and placebo-controlled.
Because people in this IGF-1 LR3 study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
A placebo (an inactive look-alike) gave the IGF-1 LR3 group a baseline to be compared against.
What Was Measured
Outcome measures were lumbar spine (1° endpoint: postero-anterior [PA] spine), hip, and radius aBMD by dual-energy X-ray absorptiometry (DXA), and vertebral, tibial, and radial volumetric BMD (vBMD) and estimated strength by high-resolution peripheral quantitative computed tomography (HR-pCT) (for extremity measurements) and multi-detector computed tomography (for vertebral measurements).
The subject headings attached to it are Absorptiometry, Photon, Anorexia Nervosa, Bone Density, Insulin-Like Growth Factor I, Lumbar Vertebrae, Recombinant Proteins and Risedronic Acid.
The authors tagged it with the keywords ANABOLICS, ANTIRESORPTIVES, DXA and NUTRITION.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of IGF-1 LR3 and Mecasermin (rhIGF-1) in 90 women.
The publication is from 2021 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.
More context: the IGF-1 LR3 compound page and the Mecasermin (rhIGF-1) compound page, all human trials.
Our Notes on the Compounds
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Mecasermin (rhIGF-1): FDA-approved recombinant human IGF-1 for severe primary IGF-1 deficiency in children; distinct from IGF-1 LR3 and IGF-1 DES.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.